← Eichor
Condition: Mycobacterial Infection Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mycobacterial Infection

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
Phase N/A · 1 location(s) · Beijing Children's Hospital · NCT03625739Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin
Phase 1 · 1 location(s) · Brigham and Women's Hospital · NCT05069688Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT
Phase N/A · 1 location(s) · Mahidol University · NCT06700876Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
Phase N/A · 1 location(s) · University of Oxford · NCT05571735Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic F
Phase N/A · 1 location(s) · Ospedale San Raffaele · NCT06413459Integrating HIV Prevention With TB Household Contact Evaluation in Uganda
NA · 1 location(s) · University of Washington · NCT07119359Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Phase N/A · 1 location(s) · University of Namibia · NCT05022238ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74
Phase 1 · 4 location(s) · Quratis Inc. · NCT06714513Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in P
Phase 3 · 8 location(s) · Chengdu CoenBiotech Co., Ltd · NCT07152639Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006Safety of Administering Isoniazid to SLE Patients to Prevent TB
Phase 2/Phase 3 · 1 location(s) · Universitas Padjadjaran · NCT06618573Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)
Phase 2 · 2 location(s) · Barwon Health · NCT06481163Tuberculosis in Rural and Malnourished Populations
NA · 1 location(s) · University of Virginia · NCT06971952Rapid Research in Diagnostics Development for TB Network
NA · 16 location(s) · University of California, San Francisco · NCT04923958TGF β 1 Expression Related Gene Polymorphism
Phase N/A · 1 location(s) · Aswan University · NCT0668369018F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients
Phase N/A · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07077213Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
Phase 2 · 8 location(s) · Kevin Winthrop · NCT05730283Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT05597280Adjunctive Doxycycline for Central Nervous System Tuberculosis
Phase 2 · 6 location(s) · National University Hospital, Singapore · NCT06446245The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in
Phase 4 · 1 location(s) · National Taiwan University Hospital · NCT05588492Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure
Phase N/A · 2 location(s) · Research Center Borstel · NCT07369414Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Phase 2 · 11 location(s) · University College, London · NCT06114628Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477ESAT6/CFP10 Skin Testing for TB Infection in Rheumatologic Patients
Phase N/A · 2 location(s) · Chinese University of Hong Kong · NCT06796647Diagnostic Utility of Mycobacterium Tuberculosis Cell-free DNA
Phase N/A · 1 location(s) · Chinese University of Hong Kong · NCT06439810Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tube
Phase 3 · 5 location(s) · Huashan Hospital · NCT05081401Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial
Phase 3 · 8 location(s) · Kaohsiung Veterans General Hospital. · NCT06727864Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
NA · 1 location(s) · University of California, San Francisco · NCT05553236Precision Rifampin Trial for Personalized Dosing
Phase 1 · 1 location(s) · University of Virginia · NCT06318416Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Phase 2/Phase 3 · 50 location(s) · The University of Queensland · NCT04310930
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.